# Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

> **NCT00005593** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** carboplatin
- **DRUG:** fludarabine phosphate
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00005593
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2002-04
- **Final completion:** 2003-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2010-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005593, "Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*